Analyst Price Targets — VTGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 7:21 pm | Andrew Tsai | Jefferies | $0.90 | $0.86 | StreetInsider | Jefferies Downgrades VistaGen Therapeutics (VTGN) to Hold |
| December 17, 2025 3:48 pm | — | Stifel Nicolaus | $1.00 | $0.79 | TheFly | Vistagen downgraded to Hold at Stifel after PALISADE-3 study disappoints |
| November 17, 2025 2:26 pm | Paul Mattheis | Stifel Nicolaus | $12.00 | $4.60 | StreetInsider | Stifel Reiterates Buy Rating on VistaGen Therapeutics (VTGN) |
| July 22, 2022 11:35 am | Andrew Tsai | Jefferies | $6.00 | $4.38 | TheFly | VistaGen Therapeutics downgraded to Hold from Buy at Jefferies |
Latest News for VTGN
Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies
Repeat dose of fasedienol demonstrated favorable safety and tolerability similar to single dose Efficacy signals were observed across primary and secondary endpoints in repeat dose and single dose Prespecified analysis of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement Efficacy signals and responder analyses provide additional supportive evidence for…
NORTH PALM BEACH, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the “Company”, or “SRX”), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that it has acquired a stake in Vistagen Therapeutics, Inc. (Vistagen) (NASDAQ: VTGN), a late clinical-stage…
SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J.
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VTGN.
U.S. House Trading
No House trades found for VTGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.